The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development ...
The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...
Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of cataplexy or excessive ...
LONDON--(BUSINESS WIRE)--The Pharmaceutical Formulation Equipment market will register an incremental spend of about USD 7.35 billion, growing at a CAGR of 8.42% during the five-year forecast period.
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions ( PTE ): Otsuka ...
Researchers at the University of Toronto say they have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine ...
This article previews some formulation topics discussed in the Pharma Fundamentals series, which aims to enhance learning for professionals in pharmaceutical drug development and manufacturing. It is ...
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug ...
LONDON--(BUSINESS WIRE)--Global procurement intelligence advisory firm, SpendEdge, has announced the release of their ‘Pharmaceutical Formulation Equipment Procurement Research Report.’ The insights ...
BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback